Screening patients with cirrhosis for hepatocellular carcinoma using either or both abdominal ultrasonography and serum alpha fetoprotein did not correlate with decreased HCC-related mortality, according to a study recently published in Gastroenterology.

Andrew M. Moon , MD, from the University of North Carolina School of Medicine, and colleagues performed a matched case-control study to evaluate the outcomes of HCC screening using abdominal ultrasonography (USS) and serum alpha fetoprotein (AFP). The study comprised 238 pairs of cases and matched controls.